Bacteriophage-mediated nucleic acid immunisation

被引：65

作者：

Clark, JR ^{[1
]}

March, JB ^{[1
]}

机构：

[1] Moredun Res Inst, Penicuik EH26 0PZ, Midlothian, Scotland

来源：

FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY | 2004年 / 40卷 / 01期

关键词：

DNA vaccination; bacteriophage; hepatitis B; vaccine delivery;

D O I：

10.1016/S0928-8244(03)00344-4

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Whole bacteriophage lambda particles, containing reporter genes under the control of the cytomegalovirus promoter (P-CMV), have been used as delivery vehicles for nucleic acid immunisation. Following intramuscular injection of mice with lambda-gt11 containing the gene for hepatitis B surface antigen (HBsAg), anti-HBsAg responses in excess of 150 mIU ml(-1) were detected. When isolated peritoneal macrophages were incubated with whole lambda particles containing the gene for green fluorescent protein (GFP) under the control of P-CMV, GFP antigen was detected on the macrophage surface 8 h later. Results suggested that direct targeting of antigen-presenting cells by bacteriophage 'vaccines' may occur, leading to enhanced immune responses compared to naked DNA delivery. Bacteriophage DNA vaccines offer several advantages: they do not contain antibiotic resistance genes, they offer a large cloning capacity (similar to15 kb), the DNA is protected from environmental degradation, they offer the potential for oral delivery, and large-scale production is cheap, easy and extremely rapid. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier B.V. All rights reserved.

引用

页码：21 / 26

页数：6

共 23 条

[1] ELECTRON MICROSCOPY OF IN VITRO ENDOCYTOSIS OF T2 PHAGE BY CELLS FROM RABBIT PERITONEAL EXUDATE [J].

ARONOW, R ;

SHAHAR, A ;

ARONSON, M ;

DANON, D .

JOURNAL OF EXPERIMENTAL MEDICINE, 1964, 120 (05) :943-+

[2] Bacteriophage therapy and prophylaxis: Rediscovery and renewed assessment of potential [J].

Barrow, PA ;

Soothill, JS .

TRENDS IN MICROBIOLOGY, 1997, 5 (07) :268-271

[3] A NOVEL-APPROACH TO THE ORAL DELIVERY OF MICRO-PARTICLES OR NANOPARTICLES [J].

BODMEIER, R ;

CHEN, HG ;

PAERATAKUL, O .

PHARMACEUTICAL RESEARCH, 1989, 6 (05) :413-417

[4]

Conry RM, 1996, GENE THER, V3, P67

[5]

*CTR DIS CONTR, 1987, MMWR-MORBID MORTAL W, V36, P353

[6] Delivery of DNA vaccines by attenuated intracellular bacteria [J].

Dietrich, G ;

Gentschev, I ;

Hess, J ;

Ulmer, JB ;

Kaufmann, SHE ;

Goebel, W .

IMMUNOLOGY TODAY, 1999, 20 (06) :251-253

[7] DNA VACCINES - PROTECTIVE IMMUNIZATIONS BY PARENTERAL, MUCOSAL, AND GENE-GUN INOCULATIONS [J].

FYNAN, EF ;

WEBSTER, RG ;

FULLER, DH ;

HAYNES, JR ;

SANTORO, JC ;

ROBINSON, HL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (24) :11478-11482

[8]

Gregoriadis G, 1999, CURR OPIN MOL THER, V1, P39

[9] The macrophage - a novel system to deliver gene therapy to pathological hypoxia [J].

Griffiths, L ;

Binley, K ;

Iqball, S ;

Kan, O ;

Maxwell, P ;

Ratcliffe, P ;

Lewis, C ;

Harris, A ;

Kingsman, S ;

Naylor, S .

GENE THERAPY, 2000, 7 (03) :255-262

[10] PHAGE PARTICLE-MEDIATED GENE-TRANSFER TO CULTURED MAMMALIAN-CELLS [J].

ISHIURA, M ;

HIROSE, S ;

UCHIDA, T ;

HAMADA, Y ;

SUZUKI, Y ;

OKADA, Y .

MOLECULAR AND CELLULAR BIOLOGY, 1982, 2 (06) :607-616

← 1 2 3 →